Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Oct;40(10):1011-1012.
doi: 10.1007/s40273-022-01184-0. Epub 2022 Sep 26.

Comment on "Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine"

Nikolaos Giannelos  1 , Marie Libérée Nishimwe  2 , Nicolas Lecrenier  3
Affiliations
Comment

Comment on "Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine"

Nikolaos Giannelos et al. Pharmacoeconomics. 2022 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

NG and NL are employees of GSK and hold shares in GSK. MLN is an AIXIAL Group consultant on behalf of GSK. AIXIAL received fees from GSK for this study. The authors declare no other financial and non-financial relationships and activities and no other conflicts of interest.

Comment in

Comment on

References

    1. Pieters Z, Ogunjimi B, Beutels P, Bilcke J. Cost-effectiveness analysis of herpes zoster vaccination in 50- to 85-year-old immunocompetent Belgian cohorts: a comparison between no vaccination, the adjuvanted subunit vaccine, and live-attenuated vaccine. Pharmacoeconomics. 2022;40(4):461–476. doi: 10.1007/s40273-021-01099-2. - DOI - PubMed
    1. Bilcke J, Ogunjimi B, Marais C, de Smet F, Callens M, Callaert K, et al. The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect. 2012;140(11):2096–2109. doi: 10.1017/S0950268811002640. - DOI - PubMed
    1. Bilcke J, Marais C, Ogunjimi B, van Hoek AJ, Lejeune O, Callens M, Vancorenland S, Van Kerschaver E, Callaert K, Hens N, Van Damme P, Beutels P. Cost-utility of vaccination against chickenpox in children and against herpes zoster in elderly in Belgium. Health Technology Assessment (HTA). KCE Reports 151; 2010. https://kce.fgov.be/en/publications/all-reports/cost-utility-of-vaccinat....
    1. EMA. Shingrix Summary of Product Characteristics (SmPC); 2022. https://www.ema.europa.eu/documents/product-information/shingrix-epar-pr...
    1. EMA. Zostavax Summary of Product Characteristics (SmPC); 2022. https://www.ema.europa.eu/documents/product-information/zostavax-epar-pr...